[HTML][HTML] Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments

D Gil, AG Schrum - Advances in bioscience and biotechnology …, 2013 - ncbi.nlm.nih.gov
Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …

Computational design to reduce conformational flexibility and aggregation rates of an antibody fab fragment

C Zhang, M Samad, H Yu, N Chakroun… - Molecular …, 2018 - ACS Publications
Computationally guided semirational design has significant potential for improving the
aggregation kinetics of protein biopharmaceuticals. While improvement in the global …

Engineered antibody fragments and the rise of single domains

P Holliger, PJ Hudson - Nature biotechnology, 2005 - nature.com
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

David vs. Goliath: the structure, function, and clinical prospects of antibody fragments

A Bates, CA Power - Antibodies, 2019 - mdpi.com
Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …

Antibody aggregation: insights from sequence and structure

W Li, P Prabakaran, W Chen, Z Zhu, Y Feng… - Antibodies, 2016 - mdpi.com
Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …

Antibody therapeutics, antibody engineering, and the merits of protein stability.

SJ Demarest, SM Glaser - Current opinion in drug discovery & …, 2008 - europepmc.org
Antibodies are highly soluble, multidomain proteins that are well suited for
biopharmaceutical development; however, engineering antibodies to perform novel …

Applications of single-chain variable fragment antibodies in therapeutics and diagnostics

NE Weisser, JC Hall - Biotechnology advances, 2009 - Elsevier
Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …

Aggregation, stability, and formulation of human antibody therapeutics

D Lowe, K Dudgeon, R Rouet, P Schofield… - Advances in protein …, 2011 - Elsevier
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies

SV Thakkar, N Sahni, SB Joshi, BA Kerwin… - Protein …, 2013 - Wiley Online Library
Aggregation of monoclonal antibodies is often a multi‐step process involving structural
alterations in monomeric proteins and subsequent formation of soluble or insoluble …

Bioengineering of antibody fragments: challenges and opportunities

S Pirkalkhoran, WR Grabowska, HH Kashkoli… - Bioengineering, 2023 - mdpi.com
Antibody fragments are used in the clinic as important therapeutic proteins for treatment of
indications where better tissue penetration and less immunogenic molecules are needed …